<!DOCTYPE  html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8"/><title>22 Imaging for common complications</title><link href="navigation.css" rel="stylesheet" type="text/css"/><link href="document.css" rel="stylesheet" type="text/css"/></head><body><p class="top_nav"><a href="part27.htm">&lt; Назад</a><span> | </span><a href="../index.html">Содержимое</a><span> | </span><a href="part29.htm">Далее &gt;</a></p><p style="padding-top: 4pt;padding-left: 49pt;text-indent: 0pt;text-align: left;"><a href="#bookmark28" class="s17" name="bookmark75">Chapter 22</a><a name="bookmark76">&zwnj;</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 49pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="374" height="1" alt="image" src="Image_337.png"/></span></p><p style="padding-top: 4pt;padding-left: 49pt;text-indent: 0pt;text-align: left;"><a href="part5.htm#bookmark28" class="h2">Imaging for common </a><h2 href="#bookmark28">complications</h2></p><p class="s18" style="padding-top: 9pt;padding-left: 48pt;text-indent: 0pt;line-height: 111%;text-align: left;">helen Addley, Katy hickman, and thankamma Ajithkumar</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s19" style="padding-top: 12pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">22.1 <span class="h4">Introduction</span></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Patients with cancer are prone to multiple complications, whether secondary to treat- ment or due to the cancer itself. Imaging plays a critical role in their diagnosis and evaluation. It is beyond the scope of this chapter to present a detailed review, but the imaging appearances of the most commonly encountered complications in clinical practice are outlined.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s19" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">22.2 <span class="h4">Venous thromboembolism</span></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Malignancy is a major risk factor with both cancer type and stage influencing the development of venous thromboembolism (VTE), notably pulmonary embolism (PE) and deep venous thrombosis (DVT). The highest incidence is seen in meta- static pancreatic, stomach, bladder, uterine, renal, and lung cancer. Other con- tributory risk factors include chemotherapy, radiotherapy, surgery, and immobility (Table 22.1). Cancer-associated VTE is serious and potentially life threatening, being the second leading cause of mortality in cancer patients following the dis- ease itself.<span class="s22">1 </span>Major risk factors for VTE are as follows: surgery—major abdom- inal and pelvic surgery, hip or knee replacement, postoperative intensive care; obstetrics—late pregnancy, caesarean section, puerperium; lower limb problems— fracture,  varicose  veins;  malignancy—abdominal/pelvic,  advanced/metastatic; reduced mobility—hospitalization, institutional care; miscellaneous—previous proven VTE.<span class="s22">2</span></p><p class="s28" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">22.2.1 <span class="s124">Pulmonary embolism</span></p><p class="s28" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">22.2.1.1 <span class="s66">Clinical assessment of pulmonary embolism</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">The value of clinical judgement in diagnosing pulmonary embolism (PE) has been demonstrated by several large series including Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED) II. The British Thoracic Society (BTS) guidelines<span class="s22">2 </span>require that the patient has clinical signs and symptoms compatible with</p><p class="s24" style="padding-top: 5pt;padding-left: 51pt;text-indent: 0pt;text-align: left;">Table 22.1 <span class="s25">Wells score for pe</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 51pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="319" height="1" alt="image" src="Image_338.png"/></span></p><p class="s39" style="padding-bottom: 2pt;padding-left: 51pt;text-indent: 0pt;text-align: left;">Variable                    Points</p><p style="padding-left: 51pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="319" height="1" alt="image" src="Image_339.png"/></span></p><p class="s41" style="padding-top: 2pt;padding-bottom: 2pt;padding-left: 51pt;text-indent: 0pt;text-align: left;">previous pe or dVt                +1.5</p><p style="padding-left: 51pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="324" height="1" alt="image" src="Image_340.png"/></span></p><p class="s41" style="padding-top: 2pt;padding-bottom: 2pt;padding-left: 51pt;text-indent: 0pt;text-align: left;">heart rate &gt;100 bpm               +1.5</p><p style="padding-left: 51pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="324" height="1" alt="image" src="Image_341.png"/></span></p><p class="s41" style="padding-top: 2pt;padding-bottom: 2pt;padding-left: 51pt;text-indent: 0pt;text-align: left;">recent surgery or immobilization          +1.5</p><p style="padding-left: 51pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="324" height="1" alt="image" src="Image_342.png"/></span></p><p class="s41" style="padding-top: 2pt;padding-bottom: 2pt;padding-left: 51pt;text-indent: 0pt;text-align: left;">Clinical signs of dVt               +3</p><p style="padding-left: 51pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="324" height="1" alt="image" src="Image_343.png"/></span></p><p class="s41" style="padding-top: 2pt;padding-bottom: 2pt;padding-left: 51pt;text-indent: 0pt;text-align: left;">haemoptysis                   +1</p><p style="padding-left: 51pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="324" height="1" alt="image" src="Image_344.png"/></span></p><p class="s41" style="padding-top: 2pt;padding-bottom: 2pt;padding-left: 51pt;text-indent: 0pt;text-align: left;">malignancy with active treatment          +1</p><p style="padding-left: 51pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="324" height="1" alt="image" src="Image_345.png"/></span></p><p class="s41" style="padding-top: 2pt;padding-bottom: 2pt;padding-left: 51pt;text-indent: 0pt;text-align: left;">Alternative diagnosis less likely than pe       +3</p><p style="padding-left: 51pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="319" height="1" alt="image" src="Image_346.png"/></span></p><p class="s21" style="padding-top: 1pt;padding-left: 51pt;text-indent: 0pt;line-height: 111%;text-align: left;">source: data from philip s. Wells et al. ‘excluding pulmonary embolism at the bedside without diagnostic imaging: management of patients with suspected pulmonary embolism presenting to the emergency department by using a simple clinical model and d-dimer’. <i>Annals of Internal Medicine</i>. Vol. 135, issue 2,</p><p class="s21" style="padding-left: 51pt;text-indent: 0pt;line-height: 8pt;text-align: left;">pp. 98–107. (2001) American College of physicians.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">PE, that is, breathlessness and/or tachypnoea with or without pleuritic chest pain and/or haemoptysis. In order to help standardize clinical judgement several predic- tion tools have been developed, with the most frequently used being the Well’s score. This score consists of seven questions, outlined in Table 22.1, to establish if PE is the more likely diagnosis. The modified Well’s score separates patients into a low prob- ability group (score ≤4) or high probability (<span class="s132">˃</span>4).</p><p class="s28" style="padding-top: 7pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">22.2.1.2 <span class="s66">D-dimer</span></p><p style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">For patients with a low probability of PE based on the Well’s score, the negative pre- dictive value of a D-Dimer &lt;750 μg L<span class="s22">−1 </span>is 99%. Therefore, no further testing is required for those with a normal D-dimer and a low probability clinical assessment. However, it reduces to 79% for those with a high probability of PE; as such, D-dimer assays are not recommended for patients with high pre-test probability. The utility of the D-dimer test is in a negative result which reliably excludes PE in patients with low or inter- mediate clinical probability.</p><p class="s28" style="padding-top: 7pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">22.2.1.3 <span class="s66">Computed tomographic pulmonary angiography</span></p><p style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Computed tomographic pulmonary angiography (CTPA) is the initial imaging inves- tigation recommended by both BTS and PIOPED II for all patients except those with low or intermediate clinical probability and a negative D-dimer (Figure 22.1). This method has higher specificity for diagnosis of PE, detection of alternative pathology, wider availability, and very short scanning time. Potential disadvantages include the use of iodinated contrast and the reduced sensitivity for small subsegmental thrombus when compared to pulmonary angiography. However, the widespread use of multi- slice computed tomography (CT) scanners, means that detection rates are increasing, even on standard CT imaging follow-up. Patients with a good quality negative CTPA do not require further investigation for PE.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s128" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">	</p><p style="text-indent: 0pt;text-align: left;"><span><img width="262" height="147" alt="image" src="Image_347.gif"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"><span><img width="149" height="147" alt="image" src="Image_348.gif"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s24" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 117%;text-align: left;">Fig. 22.1 <span class="s25">Axial (a) and coronal (b) CtpA images demonstrating filling defects in the right and left main pulmonary arteries and all segmental branches consistent with bilateral pulmonary emboli (white arrows).</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s28" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">22.2.1.4 <span class="s66">Ventilation/perfusion scanning</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">A ventilation/perfusion scan remains a helpful option for patients with renal im- pairment, in young patients, and pregnant women or women of reproductive age, to diagnose PE. A normal scan will reliably exclude PE. However, interpretation is only reliable when a current high-quality erect chest radiograph is available. Indeterminate scans are often seen in patients with an abnormal chest radiograph and therefore should not be performed unless the chest X-ray is normal. Further imaging is man- datory in patients with either an indeterminate lung scintigraphy scan or discordant clinical and scintigraphic probabilities. The BTS recommends that ventilation/perfu- sion scans should only be used as the initial imaging assessment when the facilities are available, the chest radiograph is normal, and further imaging is always performed following an inconclusive result.</p><p class="s28" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">22.2.1.5 <span class="s66">Echocardiography</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Both transoesophageal and transthoracic echocardiography can be diagnostic in mas- sive PE but are rarely definitive in other situations. It may be useful in critically ill patients as it can be performed at the bedside, but is not recommended for the vast majority of patients who are clinically stable enough to tolerate CTPA.</p><p class="s28" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">22.2.2 <span class="s124">Deep venous thrombosis</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Compression ultrasonography (US) is the imaging procedure of choice in patients with suspected DVT, with high specificity and sensitivity &gt;90% for proximal DVT. The principal criterion for diagnosis is the inability to completely compress the vein lumen, with supportive signs including distention of the involved vein and absence of flow on Doppler evaluation. Accuracy rates for the detection of thrombus isolated to the deep calf veins are lower and the evaluation of deep calf veins is more technic- ally challenging, in addition to being more time consuming. For patients with a high pre-test probability for acute DVT, serial US testing is recommended, with at least one additional follow-up compression US study over a one-week interval. Compression</p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">US may also be useful in the investigation of suspected PE, as 70% of patients with proven PE have proximal DVT.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s19" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">22.3 <span class="h4">Superior vena cava obstruction</span></p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Superior vena cava obstruction (SVCO) can occur either from external compression due to a mediastinal mass, or from intraluminal thrombus, usually associated with an intravascular device. Malignant causes account for approximately 65% of cases of SVCO, the most common associated malignancies being (in descending order of fre- quency) non-small cell lung cancer, small cell lung cancer, lymphoma, and metastases. The resultant clinical syndrome involves oedema of the affected areas, which can rarely cause airway or neurological compromise due to involvement of the upper respiratory tract or cerebral oedema respectively. Symptoms usually progress initially over a few weeks, then may improve somewhat as a collateral network develops.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Contrast-enhanced CT of the chest is the most useful initial imaging modality (Figure 22.2). CT phlebography, in which there is cannulation of veins within both ante-cubital fossae has been shown to be a useful technique for demonstration of the site of the occlusion and associated collateral vessels. Conventional venography is usually reserved for planning subsequent intervention, such as placement of a stent. Magnetic resonance venography may be helpful in patients with a severe con- trast allergy.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Percutaneous intravascular stenting is currently the treatment of choice. Stent place- ment is associated with more rapid improvement in symptom than chemoradiation and oedema usually resolves within 48–72 hours. Stent patency has been reported as 69–94% at 12 months with secondary interventions required in 18% of patients 12–36 months post stenting due to tumour overgrowth or thrombosis.<span class="s22">3 </span>Potential com- plications of stent placement include stent migration, pulmonary embolus, haema- toma at the puncture site, and perforation. Radiotherapy is considered only if stenting is not feasible technically or patients are unfit for the procedure. For patients with chemosensitive tumours (e.g. lymphoma, mediastinal germ cell tumours, small cell lung cancer), urgent chemotherapy is the first-line treatment.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s19" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">22.4 <span class="h4">The acute abdomen</span></p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">A number of conditions related to the malignancy itself or as a complication of treat- ment can present with acute abdominal pain and gastrointestinal symptoms in pa- tients with cancer. Surgical oncological referrals for patients presenting with an acute abdomen whilst undergoing chemotherapy include acute appendicitis, paralytic ileus, neutropenic colitis, intestinal perforation, acute intestinal obstruction, obstructed hernia, and intussusception. Clinical evaluation, particularly in the immunocom- promised patient, can be difficult as symptoms and signs may not develop until late in the course of the illness and are often non-specific.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Abdominal CT is the most valuable non-invasive and rapidly available imaging mo- dality which provides high quality reproducible problem-solving diagnostic informa- tion as well as providing an update of the disease status. The imaging appearances of</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="416" height="460" alt="image" src="Image_349.gif"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p class="s24" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 117%;text-align: left;">Fig. 22.2 <span class="s25">Axial (a) and coronal (b) contrast-enhanced Ct images demonstrate a large soft tissue mediastinal mass causing slit-like narrowing of the opacified sVC with likely invasion of the vessel wall (white arrow). in addition, there is soft tissue disease outside of the mediastinum with a conglomerate nodal mass in the right side of the neck (dotted arrows). digital subtraction angiography (c) and corresponding axial Ct images</span></p><p class="s25" style="padding-left: 5pt;text-indent: 0pt;line-height: 117%;text-align: left;">(d) show a metal stent placed in the sVC which is significantly narrowed due to extrinsic compression from tumour (arrow).</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">some of the most common causes for an acute abdomen in this population are briefly discussed in the rest of this section.</p><p class="s28" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">22.4.1 <span class="s124">Colitis</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">There are several causes for colitis in oncology patients, the most common being neu- tropenic colitis (typhlitis), pseudomembranous colitis due to <i>Clostridium difficile</i>, is- chaemia, infections related to immunodeficiency such as cytomegalovirus, and the</p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">direct effects of treatment, including radiotherapy, certain chemotherapeutic regimens, and, increasingly, immunotherapy-related colitis (discussed at the end of this chapter).</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">CT is the most sensitive method for the detection of colitis and can demonstrate concerning features for impending perforation and other associations such as mesen- teric venous thrombosis which would change management. A number of findings are common to all of the causes of colitis described here, although certain appearances may help to refine the diagnosis. The hallmark appearances of colitis on CT consist of bowel wall thickening to &gt;3 mm, mucosal enhancement, wall nodularity, the presence of air within the bowel wall (pneumatosis intestinalis), bowel dilatation, mesenteric stranding, and ascites.</p><p class="s28" style="padding-top: 7pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">22.4.1.1 <span class="s66">Neutropenic enterocolitis</span></p><p style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Neutropenic enterocolitis or typhlitis is a poorly understood entity but is thought to result from compromise of bowel wall integrity, with subsequent bacterial or fungal invasion. It is the most common final diagnosis in neutropenic patients with radio- logic bowel abnormalities.<span class="s22">4 </span>The caecum is the most common site of disease, although any segment of the small or large bowel may be involved (Figure 22.3). Pneumatosis intestinalis, the combined involvement of small and large bowel and/or disease iso- lated to the right hemicolon may be helpful pointers to this disease.</p><p class="s28" style="padding-top: 7pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">22.4.1.2 <span class="s66">Pseudomembranous colitis</span></p><p style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Pseudomembranous colitis is limited to the colon, with no small bowel involve- ment seen; it almost always involves the rectum and left hemicolon, with a pancolitis often demonstrated. Common features include low attenuation bowel wall thick- ening (creating the ‘accordion sign’), mesenteric stranding, and ascites. Abnormal CT</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 59pt;text-indent: 0pt;text-align: left;"><span><img width="302" height="244" alt="image" src="Image_350.gif"/></span></p><p class="s24" style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 117%;text-align: left;">Fig. 22.3 <span class="s25">Axial contrast-enhanced Ct image demonstrating thickening of the caecum (white straight arrow) and small bowel (curved arrow) in keeping with a typhlitis, which has been complicated by perforation and pneumoperitoneum (dotted arrow).</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="415" height="163" alt="image" src="Image_351.png"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s24" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 117%;text-align: left;">Fig. 22.4 <span class="s25">Axial contrast-enhanced Ct images of a patient with bowel ischaemia demonstrating portal venous gas (a, white arrows) and abnormal enhancement of the bowel wall (b) with mesenteric gas (white arrow) with pneumatosis (dotted arrows).</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;line-height: 12pt;text-align: justify;">appearances were seen in 50% of a series of 152 scanned hospitalized patients with</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;line-height: 12pt;text-align: left;">C. difficile <span class="p">colitis.</span></p><p class="s28" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">22.4.1.3 <span class="s66">Ischaemic colitis</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Ischaemic colitis is classically a disease of the elderly with arteriosclerotic disease. However, other precipitating causes include sudden hypotensive episodes, distal co- lonic obstruction, and vascular occlusion related to neoplasia. A segmental pattern of colitis is most commonly reported, which can be left- or right-sided, although a pancolitis can also be seen. Intramural air (Figure 22.4) is a relatively specific, but in- sensitive finding and may be associated with portal venous gas.</p><p class="s28" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">22.4.2 <span class="s124">Obstruction</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">There are multiple possible causes of intestinal obstruction in patients with cancer. Malignant large bowel obstruction is most commonly caused by colorectal cancer, with 10% of colon cancers presenting with large bowel obstruction. Less commonly, large bowel obstruction is caused by local invasion by primary tumours arising from the gallbladder, pancreas, kidneys, and ovaries. Small bowel obstruction is most com- monly caused by adhesions and peritoneal carcinomatosis, but rarer causes include metastases to the bowel wall, reported with breast cancer, melanoma, and osteosar- coma, among other tumours. Gastric outlet obstruction is most commonly caused by extrinsic compression from pancreatic cancer.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Abdominal CT is the imaging modality of choice as it enables evaluation of the site of obstruction and can determine the cause (Figure 22.5). For example, large bowel obstruction due to a polypoid tumour may demonstrate associated features such as pericolonic lymphadenopathy and extramural vascular invasion. Intussusception is seen as bowel-within-bowel with an enhancing tumour as the lead point. Obstruction due to carcinomatosis can be identified on CT as nodular peritoneal thickening or even discrete peritoneal masses. In the palliative setting malignant bowel obstruction can be alleviated by the placement of colonic stents either endoscopically or radiologically.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="417" height="185" alt="image" src="Image_352.png"/></span></p><p class="s133" style="text-indent: 0pt;line-height: 12pt;text-align: left;">(a)</p><p class="s133" style="text-indent: 0pt;line-height: 12pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s133" style="text-indent: 0pt;line-height: 12pt;text-align: left;">(a)</p><p class="s134" style="text-indent: 0pt;line-height: 12pt;text-align: left;">(b)</p><p class="s134" style="text-indent: 0pt;line-height: 12pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s134" style="text-indent: 0pt;line-height: 12pt;text-align: left;">(b)</p><p class="s24" style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 117%;text-align: left;">Fig. 22.5 <span class="s25">Abdominal radiograph (a) and corresponding axial contrast-enhanced Ct image (b) demonstrating dilated loops of large bowel (dotted arrow) with a transition point at the site of the luminal narrowing secondary to primary sigmoid tumour (white arrow).</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s28" style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">22.4.3 <span class="s124">Pneumoperitoneum</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">The presence of free intraperitoneal gas almost always indicates perforation of a viscus. Abdominal CT is the most sensitive imaging modality for the detection of free air (Figure 22.6), with up to 100% sensitivity. It may also help to localize the source of perforation often with phlegmonous changes adjacent to the perforation site. Bowel perforation can occur due to longstanding obstruction or ischaemia. Additionally, metastatic deposits can spontaneously perforate after chemotherapy, especially in lung cancer.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="416" height="176" alt="image" src="Image_353.png"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s24" style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 117%;text-align: left;">Fig. 22.6 <span class="s25">sagittal reformatted contrast-enhanced Ct image (a) demonstrating pneumoperitoneum (arrows) secondary to large bowel perforation secondary to serosal disease from ovarian carcinoma (dotted arrows). there is large bowel obstruction proximal to the soft tissue stricture with the sigmoid colon dilated up to 5 cm. Axial imaging in the same case (b) shows free intraperitoneal gas outlining the falciform ligament and extending into the lesser sac (arrows).</span></p><p class="s19" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">22.5 <span class="h4">Metastatic epidural spinal cord compression</span></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Metastatic epidural spinal cord compression (MESCC) occurs when an epidural meta- static lesion causes true displacement of the spinal cord from its normal position in the spinal canal. It is a relatively common complication of malignancy, occurring in 5–14% of cancer patients. If left untreated, virtually 100% of patients with MESCC would become paraplegic and this is therefore considered a true medical emergency requiring immediate intervention.<span class="s22">5 </span>Whilst therapy is primarily palliative, up to one- third of patients may survive beyond one year and preservation of quality of life is essential.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">As multiple studies have demonstrated a correlation between neurological function at the time of diagnosis and prognosis from MESCC, diagnosis before the develop- ment of neurological deficit is particularly important. Magnetic resonance imaging (MRI) is considered the gold standard imaging modality with sensitivity and speci- ficity &gt;90%.<span class="s22">6 </span>In particular, it has a higher sensitivity for detecting bone metastases as compared to CT, with superior depiction of soft tissues, tumour margins, neural elements, and paravertebral tumour extension. However, in patients who are unable to undergo MRI, CT provides an alternative means for assessment.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">MRI typically include sagittal T1- and T2-weighted sequences with STIR fat sup- pression (Figure 22.7) followed by relevant axial scans of the same sequences through identified regions of interest. Osteolytic metastases display low signal on T1-weighted and high or intermediate signal intensity on T2-weighted scans. Highly sclerotic metastases such as seen in breast or prostate cancer show low signal intensity on all sequences. MRI features suggestive of metastatic compression fractures include a convex posterior border of the vertebral body; abnormal signal intensity of the pedicle</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 96pt;text-indent: 0pt;text-align: left;"><span><img width="189" height="208" alt="image" src="Image_354.gif"/></span></p><p class="s24" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 117%;text-align: left;">Fig. 22.7 <span class="s25">sagittal t2-weighted mri imaging of a metastasis within the posterior elements of the second thoracic vertebra with extension into the epidural space. the lesion displaces the spinal cord with t2 high signal within the cord (white arrows). Additional intermediate to low signal deposits seen throughout the vertebrae in keeping with widespread bone metastases (dotted arrows).</span></p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">or posterior element; an epidural mass, particularly when it is encasing the theca; a focal paraspinal mass; and other spinal metastases.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s19" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">22.6 <span class="h4">Sepsis</span></p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Fever is a common symptom among patients with cancer and may be caused by a variety of factors including drugs, infection, or due to the tumour itself. Fever is the most consistent and sometimes the only sign of infection. The most common sites of infection are the respiratory tract, followed by the urinary tract, gastrointestinal system, and soft tissues. Febrile patients are usually initially assessed with a thorough history and clinical examination, chest radiography, and routine cultures. If chest radi- ography shows possible infection, then broncholaveolar lavage may be performed. In patients with persistent fever, but no evidence of respiratory tract infection a CT of chest, abdomen, and paranasal sinuses is usually performed; MRI of the head and liver, transoesophageal echocardiography, and fluorodeoxyglucose positron emission tomography/CT may be considered if the source of sepsis remains elusive.</p><p class="s28" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">22.6.1 <span class="s124">Respiratory tract infections</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Bacteria are the most frequent cause of pneumonia in immunocompromised pa- tients. The radiographic features of lobar or segmental consolidation usually do not differ from those in the general population, although there may be a delay in their appearance.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Fungal infections are important pathogens, particularly <i>Candida </i>and <i>Aspergillus fumigatus</i>. <i>Candida pneumonia </i>often occurs in association with other pathogens and in the presence of systemic disease with mucous membrane involvement. The radiographic findings vary from diffuse bilateral non-segmental opacities of varying sizes to a miliary pattern, or unilateral or bilateral lobar, or segmental consolidation (Figure 22.8). Cavitation is not thought to be a feature. <i>Aspergillus </i>in the immuno- compromised patient may be suggested by ground glass opacification, consolida- tion, poorly defined nodules, and cavitation.</p><p class="s12" style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Pneumocystis jiroveci <span class="p">(formerly </span>Pneumocystis carinii<span class="p">) is an important pathogen. Prolonged lymphopenia during or after chemotherapy increases the risk of infection. The radiologic appearances are similar to those seen in patients with AIDS, although the clinical course may be more fulminant, with a higher mortality. Radiographic fea- tures include diffuse or perihilar reticular and ill-defined ground glass opacities, which may progress within a few days to homogeneous opacification in the untreated patient (Figure 22.9).</span></p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">High-resolution thin-section CT is significantly more sensitive for the detection of pulmonary disease and several studies have demonstrated the value of CT in the evaluation of febrile neutropenic patients with a normal chest radiograph.<span class="s22">7</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s19" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">22.7 <span class="h4">Lymphangitis carcinomatosis</span></p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Lymphangitis carcinomatosis is caused by infiltration of tumour cells into the lymph- atic vessels and results histologically in thickening of the interlobular septa and of</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 53pt;text-indent: 0pt;text-align: left;"><span><img width="302" height="304" alt="image" src="Image_355.gif"/></span></p><p class="s24" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 117%;text-align: left;">Fig. 22.8 <span class="s25">Axial contrast-enhanced Ct demonstrating right upper lobar pneumonia with air bronchogram (black arrow) seen within the consolidated lung.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">the bronchovascular interstitium. The most common tumours causing this pat- tern of disease arise from bronchus, breast, pancreas, stomach, colon, and prostate. Approximately 25% of cases are due to infiltration of hilar lymph nodes causing per- ipheral lymphatic obstruction, whilst the remainder result from direct haematogenous spread to the lung interstitium.<span class="s22">8</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 53pt;text-indent: 0pt;text-align: left;"><span><img width="297" height="208" alt="image" src="Image_356.gif"/></span></p><p class="s25" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;line-height: 117%;text-align: left;"><span class="s24">Fig. 22.9 </span>Axial non-contrast Ct demonstrating bilateral diffuse ground glass opacification seen with <i>Pneumocystis jiroveci </i>pneumonia.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 59pt;text-indent: 0pt;text-align: left;"><span><img width="297" height="265" alt="image" src="Image_357.gif"/></span></p><p class="s24" style="padding-top: 7pt;padding-left: 11pt;text-indent: 0pt;line-height: 117%;text-align: left;">Fig. 22.10 <span class="s25">septal line thickening (arrows) of the right lower lobe in keeping with lymphangitis in a patient with a diagnosis of adenocarcinoma of the lung.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The chest radiographic findings are positive in approximately 50% of cases of patho- logically proven lymphangitis and include Kerley A lines, peripheral septal thickening (Kerley B lines), and fine reticulonodular opacification, which may be accompanied by hilar enlargement. The appearances may be very similar to those of pulmonary oedema, particularly in the absence of lymphadenopathy, and clinical correlation in association with previous radiographs is helpful in their differentiation.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">CT is significantly more sensitive than radiography, particularly thin-section high resolution CT (Figure 22.10). Common findings include thickening and irregularity of the fissures, thickening of the bronchovascular bundles and interlobular septa and often associated patchy air space shadowing. The nodularity of the septal thickening is not seen in pulmonary oedema and may be a helpful distinguishing feature.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s19" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">22.8 <span class="h4">Complications as a direct result of treatment</span></p><p class="s28" style="padding-top: 6pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">22.8.1 <span class="s124">Radiation-induced lung injury</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">The effects of radiation therapy are commonly seen on chest radiographs and CT. The pattern of radiation injury is described in two distinct phases. The initial phase is a pneumonitis, which typically develops 1–6 months after therapy. This phase is char- acterized by loss of type 1 pneumocytes, increased capillary permeability, interstitial oedema, alveolar capillary congestion, and inflammatory cell accumulation in the al- veolar space. CT features include ground glass opacities and consolidation.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The second phase of lung injury is fibrosis, which has a variable time course and a poorly understood mechanism of pathogenesis. More homogeneous linear or angled</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="385" height="185" alt="image" src="Image_358.png"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s24" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 117%;text-align: left;">Fig. 22.11 <span class="s25">pA Chest radiograph (a) demonstrates a well-demarcated central opacity extending either side of the mediastinum at the site of the previous radiotherapy field (white arrows). in addition there are multiple rounded opacities in keeping with pulmonary metastases seen more peripherally (dotted arrows). Axial contrast- enhanced Ct image (b) of the same patient demonstrates the clearly defined central fibrosis with abrupt change to normal lung extending across anatomical boundaries (arrows). A pulmonary metastasis is seen at the apical aspect of the left lower lobe (dotted arrow).</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">opacities may be seen on chest radiographs, with accompanying volume loss, which can distort adjacent structures. Traction bronchiectasis may be a dominant feature on CT as well as pleural thickening.<span class="s22">9 </span>Again, the appearances are usually geographically rather than anatomically distributed (Figure 22.11). If there are progressive changes beyond 18 months, an alternative diagnosis should be sought.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Other rarer manifestations of radiation-induced lung injury include hyperlucency, pleural effusions, and spontaneous pneumothorax. Second primary tumours may arise within the radiation field, particularly when radiation therapy is given in child- hood. Infection and tumour recurrence should be considered as differential diagnoses in radiation-induced lung injury. Infection is not usually confined to the radiation field, although secondary infection can occur in an area of radiation injury.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Tumour recurrence may be detected by the development of focal masses or cavita- tion on CT. FDG PET scanning can be helpful in distinguishing fibrosis from recurrent tumour. However, false positives are likely to occur if this is performed &lt;4–5 months post-completion of radiation therapy.<span class="s22">9</span></p><p class="s28" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">22.8.2 <span class="s124">Chemotherapy-induced lung injury</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Of the standard chemotherapy agents, bleomycin and methotrexate are most com- monly associated with pulmonary toxicity. Bleomycin-induced pneumonitis is dose dependent, seen at high cumulative doses, and typically presents at 1–6 months with patterns such as organizing pneumonia, hypersensitivity pneumonitis, and intersti- tial fibrosis. Methotrexate pulmonary toxicity also typically presents within the first</p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">year of therapy, this time with a non-specific interstitial pneumonia pattern of fibrosis being the most common manifestation.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s19" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">22.9 <span class="h4">Osteoporosis</span></p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Osteoporosis is increased in many cancer patients, in particular breast and prostate cancer patients receiving hormone manipulation therapy; oestrogen deprivation and androgen deprivation therapy (ADT) cause a reduction in bone mineral density (BMD) and are associated with a 40–50% increase in fracture incidence.<span class="s22">10</span></p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">BMD is assessed by dual-energy X-ray absorptiometry with measurements taken at the posterior-anterior spine, total hip, and total body. A T-score is calculated using a young adult reference group: T-score = (individual BMD − mean of young adult reference BMD population/standard deviation of young reference BMD population. Osteoporosis is defined as a t-score &lt;-2.5.</p><p class="s28" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">22.9.1 <span class="s124">Vertebral compression fractures</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">When a cancer patient develops an acute vertebral compression fracture then dis- tinction between metastasis or osteoporosis is important. Radiographs are often un- helpful in this situation and bone scintigraphy will show increased activity in either circumstance. A number of studies have shown that MRI may be helpful. Several distinguishing features have been demonstrated, although no single feature should be taken in isolation given the overlap in metastatic and benign disease.</p><p style="padding-left: 19pt;text-indent: 0pt;line-height: 12pt;text-align: justify;">MR features suggestive of acute osteoporotic compression fractures include:</p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Band-like shape of bone marrow oedema.</span></p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Spared normal bone marrow signal intensity of the vertebral body.</span></p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Retropulsion of a posterior bone fragment.</span></p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Multiple compression fractures.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s28" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">22.9.2 <span class="s124">Pelvic insufficiency fractures</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Pelvic insufficiency fractures (PIF) are a common complication of pelvic radiotherapy. One study investigating the rates of PIF in women who had received radiotherapy for cervical cancer found an incidence of 32%.<span class="s22">11 </span>Postmenopausal patients and those with decreased bone density appear to be at the highest risk.<span class="s22">11 </span>These fractures have charac- teristic imaging appearances and it is very important for prognosis and future treat- ment that they are not misinterpreted as bony metastatic disease.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The most common sites for the development of fractures are within the sacrum and ilium. These are often bilateral and symmetric. Pubic fractures have been re- ported also. Fractures may be visualized on radiographs, although these are in- sensitive. Bone scintigraphy classically shows a bilateral symmetrical pattern of increased uptake within the sacrum and ilium, giving rise to the ‘Honda sign’. CT can confirm the presence of fractures by demonstrating focal cortical disruption, a fracture line, and callus formation in the absence of osteolytic lesions or a soft tissue mass (Figure 22.12). They are demonstrated on MR as focal and often multiple</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="296" height="128" alt="image" src="Image_359.png"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s24" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 117%;text-align: left;">Fig. 22.12 <span class="s25">Coronal reformatted Ct image (a) demonstrates fracture lines and sclerosis in parallel to the sacroiliac joint (arrows). Bone scintigram study of the same patient</span></p><p class="s25" style="padding-left: 5pt;text-indent: 0pt;line-height: 10pt;text-align: left;">(b) demonstrated increased uptake in the typical h-sign.</p><p class="s131" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">images courtesy of dr h K Cheow, Cambridge university hospitals nhs Ft, uK.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">areas of marrow oedema, with low signal on T1-weighted images and high signal on STIR sequences</p><p class="s28" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">22.9.3 <span class="s124">Avascular necrosis</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Corticosteroids are a common cause of non-traumatic avascular necrosis (AVN). They form part of the treatment regimen for patients with haematological malignancies and can also be used in control of emesis for patients with cancer receiving standard chemotherapy. Corticosteroid-induced AVN most commonly affects the femoral head but can also occur at other sites such as the knee and shoulder. Patients present with insidious onset of pain and radiographs are the initial investigation, with findings such as cystic or sclerotic change, abnormal bone contours and collapse of the articular surface in advanced cases. MRI is the most sensitive modality to diagnose AVN, with findings such as diffuse oedema or focal low signal intensity lines separating an area of osteonecrosis, crescent sign (Figure 22.13). Bone scintigraphy is also useful to detect AVN, especially when there are multiple sites of involvement.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s19" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">22.10 <span class="h4">Imaging immune-related adverse events</span></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">A new form of targeted immunotherapy has recently been introduced; the class of drugs are referred to as ‘immune checkpoint inhibitors’ (ICI). Immune evasion is one of the hallmarks of cancer growth and these drugs work to inhibit the negative regula- tion of T-cells thereby stimulating the immune system to destroy cancer cells.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The monoclonal antibody ipilimumab, a drug that blocks cytotoxic T-lymphocyte- associated antigen 4 (CTLA-4), was the first ICI to be approved for the treatment of metastatic melanoma in 2011. Subsequently, a second class of drugs that block the checkpoint receptor cell death protein 1 (PD-1) were developed: nivolumab and pembrolizumab.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Overactivation of the immune system can lead to unique set of complications. Fortunately, immune-related adverse events (irAE) can often be managed effect- ively with discontinuation of the therapy and the administration of corticosteroids.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="416" height="190" alt="image" src="Image_360.png"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s24" style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 117%;text-align: left;">Fig. 22.13 <span class="s25">Coronal t1-weighted image (a) of the left hip demonstrates low signal intensity in the subchondral femoral head (white arrow) with preservation of the joint space. Corresponding axial stir image (b) demonstrates high signal intensity within the femoral head in keeping with oedema and serpiginous line (white arrow) in keeping with crescent sign.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Therefore, it is important to recognize these novel adverse events promptly with imaging.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The overall incidence of radiological abnormalities for patients with complica- tions of ipilimumab was reported as high as 31%.<span class="s22">12 </span>Whilst events can occur at any point along a patient’s treatment course, it has been shown that for ipilimumab the majority of adverse events occur during the first 12-week treatment induction period.</p><p class="s28" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">22.10.1 <span class="s124">Immune-related colitis</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: right;">After dermatologic manifestations, colitis is the most frequent irAE, typically occurring 5–10 weeks after the beginning of treatment. A case series of 16 patients with ipilimumab associated colitis described CT findings of mesenteric vessel en- gorgement (83%), bowel wall thickening (75%), and colonic distension (25%). These imaging features are non-specific, with pseudomembranous colitis, inflam- matory bowel disease, and ischaemic colitis all having similar CT appearances. Pseudomembranous colitis is associated with extensive colonic wall thickening, whether that be circumferential or eccentric, and this is often greater than that seen in any other inflammatory or infectious colitis, helping to differentiate this diagnosis. A second case series described three patterns of immune-related colitis: (1) dif- fuse colitis; (2) segmental colitis in the setting of diverticulosis; and (3) rectosigmoid colitis without diverticulosis. Segmental colitis was associated with greater mural thickening and pericolic fat stranding compared with diffuse colitis (Figure 22.14). Segmental colitis often presents with bloody diarrhoea and responds to combined corticosteroid and antibiotic therapy; whilst diffuse colitis is more frequently associ-</p><p style="padding-left: 11pt;text-indent: 0pt;line-height: 12pt;text-align: justify;">ated with watery diarrhoea and can be managed by steroids alone.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 82pt;text-indent: 0pt;text-align: left;"><span><img width="223" height="242" alt="image" src="Image_361.gif"/></span></p><p class="s24" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;line-height: 117%;text-align: left;">Fig. 22.14 <span class="s25">Axial contrast-enhanced Ct demonstrating marked mural thickening of the ascending colon with mucosal hyperenhancement (white arrow) and adjacent fat stranding (dotted arrow) in a patient with colitis.</span></p><p class="s131" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">image courtesy of dr. ed Godfrey, Cambridge university hospitals nhs Foundation trust, uK.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s28" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">22.10.2 <span class="s124">Immune-related hepatitis</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Patients presenting with immune-related hepatitis are often asymptomatic and so liver function testing is recommended prior to initiating an ICI, and then regularly prior to each infusion. The incidence of immune-related hepatitis is reported as 2–9%, with rates increasing for patients on combined therapy of nivolumab and ipilimumab. The average time of onset of hepatitis after the initiation of therapy is 12–16 weeks (after the third dose).</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: right;">The imaging findings of hepatomegaly, periportal oedema (seen as T2 high signal on MRI, or increased periportal echogenicity on US), periportal lymphadenopathy, and reduced attenuation of the liver parenchyma are non-specific, with only clinical his- tory able to distinguish immune-related from viral or alcohol induced acute hepatitis. It is also important to exclude hepatic metastases in the context of deranged liver function tests. What is more, metastases may be obscured by the reduced attenuation of the liver parenchyma secondary to hepatitis or could be confused with new geo-</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 12pt;text-align: justify;">graphic areas of low attenuation that can mimic metastases.</p><p class="s28" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">22.10.3 <span class="s124">Immune-related pneumonitis</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Pneumonitis is a rare complication seen in 1–5% of patients. Evaluation of pa- tients taking PD-1 inhibitors found the median time to develop pneumonitis was</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">2.6 months after initiation of therapy. There is a broad range of presentations from patients who are asymptomatic to those with life-threatening hypoxia. Given the po- tentially serious nature of this toxicity it is important that pneumonitis is recognized</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="341" height="118" alt="image" src="Image_362.png"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"><span><img width="168" height="118" alt="image" src="Image_363.gif"/></span></p><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s24" style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">Fig. 22.15 <span class="s25">sequential axial Ct images of the thorax each taken a month apart</span></p><p class="s25" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;line-height: 117%;text-align: left;">(a, b, c). the bilateral peripheral ground glass opacification (white arrows) improves over the first month (a, b) but then rapidly deteriorates with ground glass infiltration with associated tractional bronchiectasis throughout the lungs (c). these appearances are in keeping with an organizing pneumonia pattern of drug reaction.</p><p class="s131" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">images courtesy of dr J Babar, Cambridge university hospitals nhs Ft, uK.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">promptly; however, this is difficult as its presentation on imaging is non-specific and highly variable. Ground glass opacities, reticular opacities, and consolidation (Figure 22.15) were the most common CT findings (as is also the case for standard drug-related pneumonitis).</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">One study followed the classification of interstitial pneumonias and applied it to describe the varying patterns seen with immune-mediated pneumonitis: 65% fit a cryptogenic organizing pneumonia (COP) pattern, 15% a non-specific interstitial pneumonia pattern (NSIP), 10% a hypersensitivity pneumonitis (HP) pattern, and 10% an acute respiratory distress syndrome (ARDS) pattern.</p><p class="s28" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">22.10.4 <span class="s124">Immune-related hypophysitis</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Symptoms of headache, fatigue, hypothyroidism, hypogonadism, and hypocortisolism have a median onset of nine weeks for patients who have ipilimumab treatment associ- ated pituitary hypophysitis. It has an incidence of 2–4%, increasing to 25% for those on combined therapy. The most commonly seen MRI findings are moderate enlargement of the pituitary itself, enlargement of the stalk or infundibulum, and homogenous con- trast enhancement (Figure 22.16).</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Immune mediated hypophysitis can mimic metastatic disease; for example from melanoma, breast, or more rarely, lung cancer. It is also important to distinguish ap- pearances from pituitary macroadenomas. Macroadenomas are usually seen as a fo- cally enlarged pituitary with a normal stalk and heterogeneous enhancement.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 68pt;text-indent: 0pt;text-align: left;"><span><img width="260" height="245" alt="image" src="Image_364.gif"/></span></p><p class="s24" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;line-height: 118%;text-align: left;">Fig. 22.16 <span class="s25">sagittal t1-weighted mri following the administration of intravenous contrast medium demonstrates diffuse enlargement of the pituitary gland (white arrow) with superior displacement of the infundibulum (dotted arrow) in a patient with hypophysitis. </span><span class="s135">image courtesy of dr t das, Cambridge university hospitals nhs Ft, uK.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s19" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">22.11 <span class="h4">Summary</span></p><p class="s23" style="padding-top: 6pt;padding-left: 17pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">Complications either as a result of malignancy or as a consequence of treatment are common.</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">◆ <span class="p">Complications may mimic malignancy.</span></p><p class="s23" style="padding-top: 2pt;padding-left: 17pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">Imaging plays a critical role in the diagnostic pathway. Final diagnosis may require the use of several imaging modalities. Comprehensive clinical information is essen- tial to aid the radiologist with narrowing the differential diagnosis.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s126" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">References</p><p class="s74" style="padding-top: 5pt;padding-left: 18pt;text-indent: -10pt;text-align: left;">1. <b>Khorana AA</b>, <b>Francis CW</b>, <b>Culakova E</b>, <b>Kuderer NM</b>, <b>Lyman GH </b>(2007). Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. <i>Journal of Thrombosis &amp; Haemostasis</i>, <b>5</b>: 632–634.</p><p class="s74" style="padding-top: 1pt;padding-left: 18pt;text-indent: -10pt;text-align: left;">2. <b>British Thoracic Society Guidelines (2003)</b>. British Thoracic Society guidelines for the management of suspected acute pulmonary embolism. <i>Thorax</i>, <b>58</b>(6): 470–484.</p><p class="s74" style="padding-top: 1pt;padding-left: 18pt;text-indent: -10pt;text-align: left;">3. <b>Kalra M</b>, <b>Sen I</b>, <b>Gloviczki P </b>(2018). Endovenous and operative treatment of superior vena cava syndrome. <i>Surgical Clinics in North America</i>, <b>98</b>(2): 321–335.</p><p class="s74" style="padding-top: 1pt;padding-left: 18pt;text-indent: -10pt;text-align: left;">4. <b>Kirkpatrick IDC</b>, <b>Greenberg HM </b>(2003). Gastrointestinal complications in the neutropenic patient: characterization and differentiation with abdominal CT. <i>Radiology</i>, <b>226</b>(3):668–674.</p><p class="s74" style="padding-top: 1pt;padding-left: 18pt;text-indent: -10pt;text-align: left;">5. <b>Kaloostian PE</b>, <b>Yurter A</b>, <b>Zadnik PL</b>, <b>Sciubba DM</b>, <b>Gokaslan ZL </b>(2014). Current paradigms for metastatic spinal disease: An evidence-based review. <i>Annals of Surgical Oncology</i>, <b>21</b>(1): 248–262.</p><p class="s74" style="padding-top: 4pt;padding-left: 25pt;text-indent: -9pt;text-align: left;">6. <b>Smoker WR</b>, <b>Godersky JC</b>, <b>Knutzon RK</b>, <b>Keyes WD</b>, <b>Norman D</b>, <b>Bergman W </b>(1987). The role of MR imaging in evaluating metastatic spinal disease. <i>American Journal of Roentgenology</i>, <b>149</b>(6): 1241–1248.</p><p class="s74" style="padding-top: 1pt;padding-left: 25pt;text-indent: -9pt;text-align: left;">7. <b>Gerritsen MG</b>, <b>Willemink MJ</b>, <b>Pompe E, et al. </b>(2017). Improving early diagnosis of pulmonary infections in patients with febrile neutropenia using low-dose chest computed tomography. <i>PLoS One</i>, <b>12</b>(2): 1–13.</p><p class="s74" style="padding-top: 1pt;padding-left: 25pt;text-indent: -9pt;text-align: left;">8. <b>Stein MG</b>, <b>Mayo J</b>, <b>Müller N</b>, <b>Aberle DR</b>, <b>Webb WR</b>, <b>Gamsu G </b>(1987). Pulmonary lymphangitic spread of carcinoma: appearance on CT scans. <i>Radiology</i>, <b>162</b>(2): 371–375.</p><p class="s74" style="padding-top: 1pt;padding-left: 16pt;text-indent: 0pt;line-height: 11pt;text-align: left;">9. <b>Giridhar P</b>, <b>Mallick S</b>, <b>Rath GK</b>, <b>Julka PK </b>(2015). Radiation induced lung</p><p class="s74" style="padding-left: 25pt;text-indent: 0pt;line-height: 11pt;text-align: left;">injury: prediction, assessment and management. <i>Asian Pacific Journal of Cancer Prevention</i>,</p><p class="s75" style="padding-left: 25pt;text-indent: 0pt;line-height: 11pt;text-align: left;">16<span class="s74">(7): 2613–2617.</span></p><p class="s74" style="padding-top: 1pt;padding-left: 25pt;text-indent: -13pt;text-align: left;">10. <b>Coleman R</b>, <b>Body JJ</b>, <b>Aapro M</b>, <b>Hadji P</b>, <b>Herrstedt J </b>(2014). Bone health in cancer patients: ESMO clinical practice guidelines. <i>Annals of Oncology</i>, <b>25</b>(August): 124–137.</p><p class="s74" style="padding-top: 1pt;padding-left: 25pt;text-indent: -13pt;text-align: left;">11. <b>Uezono H</b>, <b>Tsujino K</b>, <b>Moriki K, et al. </b>(2013). Pelvic insufficiency fracture after definitive radiotherapy for uterine cervical cancer: retrospective analysis of risk factors. <i>Journal of Radiation Research</i>, <b>54</b>(6): 1102–1109.</p><p class="s74" style="padding-top: 1pt;padding-left: 25pt;text-indent: -13pt;text-align: left;">12. <b>Kwak JJ</b>, <b>Tirumani SH</b>, <b>Van den Abbeele AD</b>, <b>Koo PJ</b>, <b>Jacene HA </b>(2015). Cancer immunotherapy: imaging assessment of novel treatment response patterns and immune- related adverse events. <i>RadioGraphics</i>, <b>35</b>(2): 424–437.</p><p class="nav">&nbsp;&nbsp;</p><p class="nav">&nbsp;</p><p class="nav"><a href="part27.htm">&lt; Назад</a><span> | </span><a href="../index.html">Содержимое</a><span> | </span><a href="part29.htm">Далее &gt;</a></p><p class="nav">&nbsp;&nbsp;</p></body></html>
